Gilead to present HIV research findings at conference
Gilead (GILD) announced the upcoming presentation of HIV research findings at the International Congress on Drug Therapy in HIV Infection, ...
BioSpace3d
Gilead Beats Q3 Expectations Fueled by HIV Drug Sales, Raises Full-Year Guidance
BMO Capital Markets analyst Evan Seigerman in a note to investors called Gilead’s third-quarter performance “consistent” and ...
FiercePharma3d
Gilead's CAR-T sales stagnate as Trodelvy takes another impairment hit
Despite a mission to become a dominant cancer drug player, Gilead Sciences has as of late been locked in on its ...
Why Gilead's Solid Q3 Earnings Could Point To A Dividend Surprise Next Year
Gilead Sciences' Q3 2024 results exceeded expectations, driven by a strong performance of the HIV portfolio. Read why I ...
Zacks.com on MSN3d
Gilead Beats on Q3 Earnings and Sales, Raises Annual Outlook
Gilead Sciences, Inc. GILD reported better-than-expected third-quarter results and raised its annual earnings guidance.
Gilead increases 2024 outlook, expects new drug filing by end of year
Gilead Sciences ( GILD) increased its growth forecast for the year on strong third quarter results, marking a shift away from ...
Gilead 3rd-quarter results beat Wall Street estimates, raises outlook
He said Gilead plans to file before the end of this year for U.S. regulatory approval of lenacapavir, a twice-yearly ...
Gilead Sciences: Strong Financial Performance and Promising Pipeline Drive Buy Rating
Leerink Partners analyst Daina Graybosch has maintained their bullish stance on GILD stock, giving a Buy rating yesterday. Daina ...
Gilead’s third-quarter earnings beat by a wide margin, and biotech raises guidance
Gilead Sciences Inc.’s stock rose 2.7% in after-hours trading Wednesday, after the biotech blew past third-quarter earnings ...
Gilead Sciences Tops Estimates in Q3
Gilead Sciences posted robust revenue and EPS growth, exceeding expectations, and management raised full-year guidance.
Late-Breaking Clinical Data and Real-World Evidence Presented at HIV Glasgow as Gilead Extends Leadership Efforts Toward Ending the Epidemic
Gilead Sciences, Inc. (Nasdaq: GILD) today announced the upcoming presentation of HIV research findings at the International ...
Business Wire3d
Gilead Sciences Announces Third Quarter 2024 Financial Results
Gilead Sciences, Inc. (Nasdaq: GILD) announced today its third quarter 2024 results of operations. “Gilead’s third quarter results are the strongest o ...